An update on lipophilic efficiency as an important metric in drug design

References

• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711–715. doi: 10.1038/nrd1470
   PubMed Web of Science ®Google Scholar
• Maurer TS, Edwards M, Hepworth D, et al. Designing small molecules for therapeutic success: A contemporary perspective. Drug Discov Today. 2022;27(2):538–546. doi: 10.1016/j.drudis.2021.09.017
   PubMed Web of Science ®Google Scholar
• Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol. 2011;24(9):1420–1456. doi: 10.1021/tx200211v
   PubMed Web of Science ®Google Scholar
• Taylor D. The pharmaceutical industry and the future of drug development. In: Hester RE, Harrison RM, editors. Pharmaceuticals in the Environment. The Royal Society of Chemistry; 2015. doi: 10.1039/9781782622345-00001
   Google Scholar
• Stepan AF, Walker DP, Bauman J, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol. 2011;24(9):1345–1410. doi: 10.1021/tx200168d
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett. 2008;18(17):4872–4875. doi: 10.1016/j.bmcl.2008.07.071
   PubMed Web of Science ®Google Scholar
• Freeman-Cook KD, Hoffman RL, Johnson TW. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry. Future Med Chem. 2013;5(2):113–115. doi: 10.4155/fmc.12.208
   PubMed Web of Science ®Google Scholar
• Maurer TS, Smith D, Beaumont K, et al. Dose predictions for drug design. J Med Chem. 2020;63(12):6423–6435. doi: 10.1021/acs.jmedchem.9b01365
   PubMed Web of Science ®Google Scholar
• Miller RR, Madeira M, Wood HB, et al. Integrating the impact of lipophilicity on potency and pharmacokinetic parameters enables the use of diverse chemical space during small molecule drug optimization. J Med Chem. 2020;63(21):12156–12170. doi: 10.1021/acs.jmedchem.9b01813
   PubMed Web of Science ®Google Scholar
• Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov. 2010;5(3):235–248. doi: 10.1517/17460441003605098
   PubMed Web of Science ®Google Scholar
• Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov. 2012;7(10):863–875. doi: 10.1517/17460441.2012.714363
   PubMed Web of Science ®Google Scholar
• Wenlock MC, Potter T, Barton P, et al. A method for measuring the lipophilicity of compounds in mixtures of 10. J Biomol Screen. 2011;16(3):348–355. doi: 10.1177/1087057110396372
   PubMedGoogle Scholar
• Smith DDA, Kalgutkar AS, van de Waterbeemd H, et al. Physicochemistry. In: Smith, DA, Allerton, C, Kalgutkar, AS, et al., editors. Methods and principles in medicinal chemistry, pharmacokinetics and metabolism in drug design. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2012. p. 1–17.
   Google Scholar
• Manallack DT. The pK(a) distribution of drugs: application to drug discovery. Perspect Medicin Chem. 2007;1:25–38. doi: 10.1177/1177391X0700100003
   PubMedGoogle Scholar
• Johnson TW, Gallego RA, Edwards MP. Lipophilic efficiency as an important metric in drug design. J Med Chem. 2018;61(15):6401–6420. doi: 10.1021/acs.jmedchem.8b00077
   PubMed Web of Science ®Google Scholar
• Liu X, Testa B, Fahr A. Lipophilicity and its relationship with passive drug permeation. Pharm Res. 2011;28(5):962–977. doi: 10.1007/s11095-010-0303-7
   PubMed Web of Science ®Google Scholar
• Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett. 2009;19(10):2844–2851. doi: 10.1016/j.bmcl.2009.03.109
   PubMed Web of Science ®Google Scholar
• Freire E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today. 2008;13(19–20):869–874. doi: 10.1016/j.drudis.2008.07.005
   PubMed Web of Science ®Google Scholar
• Ruben AJ, Kiso Y, Freire E. Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem Biol Drug Des. 2006;67(1):2–4. doi: 10.1111/j.1747-0285.2005.00314.x
   PubMed Web of Science ®Google Scholar
• Motiejunas D, Wade RC. 4.09 - Structural, Energetic, and Dynamic Aspects of Ligand–Receptor Interactions. In: Taylor JB, Triggle DJ, editors. Comprehensive medicinal chemistry II. Elsevier; 2007. p. 193–213. doi: 10.1016/B0-08-045044-X/00250-9
   Google Scholar
• Martin MT, Koza-Taylor P, Di L, et al. Early drug-induced liver injury risk screening: “Free,” as good as it gets. Toxicol Sci. 2022;188(2):208–218. doi: 10.1093/toxsci/kfac054
   PubMed Web of Science ®Google Scholar
• Norman BH. Drug Induced Liver Injury (DILI). Mechanisms and medicinal chemistry avoidance/mitigation strategies. J Med Chem. 2020;63(20):11397–11419. doi: 10.1021/acs.jmedchem.0c00524
   PubMed Web of Science ®Google Scholar
• Edwards MP, Price DA, et al. Chapter 23 - Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks. In: Macor JE, editor. Annual Reports in Medicinal Chemistry. Vol. 45. Academic Press; 2010. p. 380–391. doi: 10.1016/S0065-7743(10)45023-X
   Google Scholar
• Johnson TW, Dress KR, Edwards M. Using the Golden Triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett. 2009;19(19):5560–5564. doi: 10.1016/j.bmcl.2009.08.045
   PubMed Web of Science ®Google Scholar
• Yukawa T, Naven R. Utility of physicochemical properties for the prediction of toxicological outcomes: Takeda perspective. ACS Med Chem Lett. 2020;11(2):203–209. doi: 10.1021/acsmedchemlett.9b00536
   PubMed Web of Science ®Google Scholar
• Shamovsky I, Connolly S, David L, et al. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships. J Med Chem. 2008;51(5):1162–1178. doi: 10.1021/jm070543k
   PubMed Web of Science ®Google Scholar
• Dash RP, Thomas JA, Rosenfeld C, et al. Protein binding and stability of drug candidates: The Achilles’ heel in in vitro potency assays. Eur J Drug Metab Pharmacokinet. 2020;45(4):427–432. doi: 10.1007/s13318-020-00619-3
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des. 2001;15(3):273–286. doi: 10.1023/a:1008192010023.
   PubMed Web of Science ®Google Scholar
• Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6(11):881–890. doi: 10.1038/nrd2445
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Keseru GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13(2):105–121. doi: 10.1038/nrd4163
   PubMed Web of Science ®Google Scholar
• Leeson PD, Bento AP, Gaulton A, et al. Target-based evaluation of “drug-like” properties and ligand efficiencies. J Med Chem. 2021;64(11):7210–7230. doi: 10.1021/acs.jmedchem.1c00416
   PubMed Web of Science ®Google Scholar
• Ryckmans T, Edwards MP, Horne VA, et al. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: a Lipophilic Efficiency (LipE) analysis. Bioorg Med Chem Lett. 2009;19(15):4406–4409. doi: 10.1016/j.bmcl.2009.05.062
   PubMed Web of Science ®Google Scholar
• Stepan AF, Kauffman GW, Keefer CE, et al. Evaluating the differences in cycloalkyl ether metabolism using the design parameter “lipophilic metabolism efficiency” (LipMetE) and a matched molecular pairs analysis. J Med Chem. 2013;56(17):6985–6990. doi: 10.1021/jm4008642
   PubMed Web of Science ®Google Scholar
• Cecere G, Guasch L, Olivares-Morales AM, et al. LipMetE (Lipophilic Metabolism Efficiency) as a simple guide for half-life and dosing regimen prediction of oral drugs. ACS Med Chem Lett. 2022;13(9):1444–1451. doi: 10.1021/acsmedchemlett.2c00183
   PubMed Web of Science ®Google Scholar
• Tarcsay A, Nyiri K, Keseru GM. Impact of lipophilic efficiency on compound quality. J Med Chem. 2012;55(3):1252–1260. doi: 10.1021/jm201388p
   PubMed Web of Science ®Google Scholar
• Bagdanoff JT, Chen Z, Acker M, et al. Optimization of fused bicyclic allosteric SHP2 inhibitors. J Med Chem. 2019;62(4):1781–1792. doi: 10.1021/acs.jmedchem.8b01725
   PubMed Web of Science ®Google Scholar
• Harada K, Mizukami J, Watanabe T, et al. Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure. Bioorg Med Chem Lett. 2019;29(3):373–379. doi: 10.1016/j.bmcl.2018.12.041
   PubMed Web of Science ®Google Scholar
• Hoegenauer K, Kallen J, Jimenez-Nunez E, et al. Structure-based and property-driven optimization of N-Aryl Imidazoles toward potent and selective oral RORgammat inhibitors. J Med Chem. 2019;62(23):10816–10832. doi: 10.1021/acs.jmedchem.9b01291
   PubMed Web of Science ®Google Scholar
• Sarver P, Acker M, Bagdanoff JT, et al. 6-amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors. J Med Chem. 2019;62(4):1793–1802. doi: 10.1021/acs.jmedchem.8b01726
   PubMed Web of Science ®Google Scholar
• Mammoliti O, Palisse A, Joannesse C, et al. Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem. 2021;64(9):6037–6058. doi: 10.1021/acs.jmedchem.1c00138
   PubMed Web of Science ®Google Scholar
• Tawada M, Fushimi M, Masuda K, et al. Discovery of a Novel and Brain-Penetrant O-GlcNAcase inhibitor via virtual screening, structure-based analysis, and rational lead optimization. J Med Chem. 2021;64(2):1103–1115. doi: 10.1021/acs.jmedchem.0c01712
   PubMed Web of Science ®Google Scholar
• Humphreys PG, Anderson NA, Bamborough P, et al. Identification and optimization of a ligand-efficient Benzoazepinone Bromodomain and Extra Terminal (BET) family acetyl-lysine mimetic into the oral candidate quality molecule I-BET432. J Med Chem. 2022;65(22):15174–15207. doi: 10.1021/acs.jmedchem.2c01102
   PubMed Web of Science ®Google Scholar
• Kajita Y, Ikeda S, Yoshikawa M, et al. Discovery of Novel 3-Piperidinyl Pyridine derivatives as highly potent and selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors. J Med Chem. 2022;65(4):3343–3358. doi: 10.1021/acs.jmedchem.1c01898
   PubMed Web of Science ®Google Scholar
• Zhang W, Vadlakonda S, Wu M, et al. Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon. Bioorg Med Chem. 2022;73:117035. doi: 10.1016/j.bmc.2022.117035
   PubMed Web of Science ®Google Scholar
• Bradley E, Fusani L, Chung CW, et al. Structure-guided design of a domain-selective bromodomain and extra Terminal N-Terminal Bromodomain chemical probe. J Med Chem. 2023;66(23):15728–15749. doi: 10.1021/acs.jmedchem.3c00906
   PubMed Web of Science ®Google Scholar
• Gallego RA, Bernier L, Chen H, et al. Design and synthesis of functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine inhibitors of hematopoietic progenitor kinase 1. J Med Chem. 2023;66(7):4888–4909. doi: 10.1021/acs.jmedchem.2c02038
   PubMed Web of Science ®Google Scholar
• Tamayo NA, Bourbeau MP, Allen JR, et al. Targeting the mitotic kinesin KIF18A in chromosomally unstable cancers: hit optimization toward an in vivo chemical probe. J Med Chem. 2022;65(6):4972–4990. doi: 10.1021/acs.jmedchem.1c02030
   PubMed Web of Science ®Google Scholar
• Murphy ST, Atienza J, Brown JW, et al. Optimization of mTOR inhibitors using property-based drug design and free-Wilson analysis for improved in vivo efficacy. ACS Med Chem Lett. 2023;14(11):1544–1550. doi: 10.1021/acsmedchemlett.3c00351
   PubMed Web of Science ®Google Scholar
• Barnes L, Blaber H, Brooks DTK, et al. Free-Wilson analysis of comprehensive data on phosphoinositide-3-kinase (PI3K) inhibitors reveals importance of N-methylation for PI3Kdelta activity. J Med Chem. 2019;62(22):10402–10422. doi: 10.1021/acs.jmedchem.9b01499
   PubMed Web of Science ®Google Scholar
• Hopkins BT, Bame E, Bell N, et al. Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton’s tyrosine kinase inhibitors. Bioorg Med Chem. 2021;44:116275. doi: 10.1016/j.bmc.2021.116275
   PubMed Web of Science ®Google Scholar
• Casimiro-Garcia A, Allais C, Brennan A, et al. Discovery of a series of pyrimidine carboxamides as inhibitors of Vanin-1. J Med Chem. 2022;65(1):757–784. doi: 10.1021/acs.jmedchem.1c01849
   PubMed Web of Science ®Google Scholar
• Futatsugi K, Cabral S, Kung DW, et al. Discovery of Ervogastat (PF-06865571): a potent and selective inhibitor of Diacylglycerol Acyltransferase 2 for the treatment of non-alcoholic Steatohepatitis. J Med Chem. 2022;65(22):15000–15013. doi: 10.1021/acs.jmedchem.2c01200
   PubMed Web of Science ®Google Scholar
• Goldberg FW, Kettle JG, Lamont GM, et al. Discovery of clinical candidate AZD0095, a selective inhibitor of Monocarboxylate Transporter 4 (MCT4) for oncology. J Med Chem. 2023;66(1):384–397. doi: 10.1021/acs.jmedchem.2c01342
   PubMed Web of Science ®Google Scholar
• Humphreys PG, Atkinson SJ, Bamborough P, et al. Design, synthesis, and characterization of I-BET567, a Pan-Bromodomain and extra terminal (BET) Bromodomain oral candidate. J Med Chem. 2022;65(3):2262–2287. doi: 10.1021/acs.jmedchem.1c01747
   PubMed Web of Science ®Google Scholar
• Shen S, Hadley M, Ustinova K, et al. Discovery of a New Isoxazole-3-hydroxamate-based histone deacetylase 6 inhibitor SS-208 with antitumor activity in syngeneic melanoma mouse models. J Med Chem. 2019;62(18):8557–8577. doi: 10.1021/acs.jmedchem.9b00946
   PubMed Web of Science ®Google Scholar
• Cheng H, Orr STM, Bailey S, et al. Structure-based drug design and synthesis of PI3Kalpha-selective inhibitor (PF-06843195). J Med Chem. 2021;64(1):644–661. doi: 10.1021/acs.jmedchem.0c01652
   PubMed Web of Science ®Google Scholar
• Noonepalle S, Shen S, Ptacek J, et al. Rational design of suprastat: a novel selective histone deacetylase 6 inhibitor with the ability to potentiate immunotherapy in melanoma models. J Med Chem. 2020;63(18):10246–10262. doi: 10.1021/acs.jmedchem.0c00567
   PubMed Web of Science ®Google Scholar
• Clegg MA, Bamborough P, Chung CW, et al. Application of Atypical Acetyl-lysine Methyl Mimetics in the development of selective inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. J Med Chem. 2020;63(11):5816–5840. doi: 10.1021/acs.jmedchem.0c00075
   PubMed Web of Science ®Google Scholar
• Goldberg FW, Finlay MRV, Ting AKT, et al. The discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a potent and selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. J Med Chem. 2020;63(7):3461–3471. doi: 10.1021/acs.jmedchem.9b01684
   PubMed Web of Science ®Google Scholar
• Goldberg FW, Ting AKT, Beattie D, et al. Optimization of hERG and pharmacokinetic properties for basic Dihydro-8H-purin-8-one inhibitors of DNA-PK. ACS Med Chem Lett. 2022;13(8):1295–1301. doi: 10.1021/acsmedchemlett.2c00172
   PubMed Web of Science ®Google Scholar
• Davoren JE, Nason D, Coe J, et al. Discovery and lead optimization of Atropisomer D1 agonists with reduced desensitization. J Med Chem. 2018;61(24):11384–11397. doi: 10.1021/acs.jmedchem.8b01622
   PubMed Web of Science ®Google Scholar
• Cisar JS, Pietsch C, DeRatt LG, et al. N-Heterocyclic 3-pyridyl carboxamide inhibitors of DHODH for the treatment of acute myelogenous leukemia. J Med Chem. 2022;65(16):11241–11256. doi: 10.1021/acs.jmedchem.2c00788
   PubMed Web of Science ®Google Scholar
• Cioffi CL, Racz B, Varadi A, et al. Design, synthesis, and preclinical efficacy of novel nonretinoid antagonists of retinol-binding Protein 4 in the mouse model of hepatic steatosis. J Med Chem. 2019;62(11):5470–5500. doi: 10.1021/acs.jmedchem.9b00352
   PubMed Web of Science ®Google Scholar
• Xiao P, Duan Z, Liu Z, et al. Rational design of RNA Demethylase FTO inhibitors with enhanced Antileukemia drug-like properties. J Med Chem. 2023;66(14):9731–9752. doi: 10.1021/acs.jmedchem.3c00543
   PubMed Web of Science ®Google Scholar
• Islam MS, Ghawas HM, El-Senduny FF, et al. Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents. Bioorg Chem. 2019;82:423–430. doi: 10.1016/j.bioorg.2018.10.036
   PubMed Web of Science ®Google Scholar
• Protopopov MV, Vdovin VS, Starosyla SA, et al. Flavone inspired discovery of benzylidenebenzofuran-3(2H)-ones (aurones) as potent inhibitors of human protein kinase CK2. Bioorg Chem. 2020;102:104062. doi: 10.1016/j.bioorg.2020.104062
   PubMed Web of Science ®Google Scholar
• Epplin MP, Mohan A, Harris LD, et al. Discovery of dihydropyrrolo[1,2-a]pyrazin-3(4H)-one-based second-generation GluN2C- and GluN2D-selective positive allosteric modulators (PAMs) of the N-methyl-d-aspartate (NMDA) receptor. J Med Chem. 2020;63(14):7569–7600. doi: 10.1021/acs.jmedchem.9b01733
   PubMed Web of Science ®Google Scholar
• Girst G, Otvos SB, Fulop F, et al. Pharmacokinetics-driven evaluation of the antioxidant activity of Curcuminoids and their major reduced metabolites-a medicinal chemistry approach. Molecules. 2021;26(12). doi: 10.3390/molecules26123542
   PubMed Web of Science ®Google Scholar
• Kutkat O, Kandeil A, Moatasim Y, et al. In vitro and in vivo antiviral studies of New Heteroannulated 1,2,3-Triazole glycosides targeting the neuraminidase of influenza a viruses. Pharmaceuticals (Basel). 2022;(15):3. doi: 10.3390/ph15030351
   PubMedGoogle Scholar
• Oboh E, Teixeira JE, Schubert TJ, et al. Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633. Bioorg Med Chem. 2023;86:117295. doi: 10.1016/j.bmc.2023.117295
   PubMed Web of Science ®Google Scholar
• Eskandrani R, Al-Rasheed LS, Ansari SA, et al. Targeting transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine derivatives as anticancer agents: design, synthesis, biological evaluation and in silico studies. Molecules. 2023;28(11). doi: 10.3390/molecules28114271
   Web of Science ®Google Scholar
• Hegazy A, Mahmoud SH, Elshaier Y, et al. Antiviral activities of plant-derived indole and beta-carboline alkaloids against human and avian influenza viruses. Sci Rep. 2023;13(1):1612. doi: 10.1038/s41598-023-27954-0
   PubMed Web of Science ®Google Scholar
• Li Z, Xu X, Hou J, et al. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold. Bioorg Chem. 2018;77:429–435. doi: 10.1016/j.bioorg.2018.01.039
   PubMed Web of Science ®Google Scholar
• Babin V, Tournier BB, Davis A, et al. Design of iodinated radioligands for SPECT imaging of central human 5-HT(4)R using a ligand lipophilicity efficiency approach. Bioorg Chem. 2020;96:103582. doi: 10.1016/j.bioorg.2020.103582
   PubMed Web of Science ®Google Scholar
• Mavrova A, Dimov S, Sulikovska I, et al. Design, Cytotoxicity and Antiproliferative Activity of 4-Amino-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylates against MFC-7 and MDA-MB-231 breast cancer cell lines. Molecules. 2022;27(10). doi: 10.3390/molecules27103314
   PubMed Web of Science ®Google Scholar
• Ji X, Ge L, Ma R, et al. Screening potential ligands of endothelin receptor a from Choerospondias axillaris and evaluation of their drug-like properties by affinity chromatographic methods. J Pharm Biomed Anal. 2023;226:115240. doi: 10.1016/j.jpba.2023.115240
   PubMed Web of Science ®Google Scholar
• Li Z, Liu C, Shi W, et al. Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold. Bioorg Med Chem. 2018;26(3):703–711. doi: 10.1016/j.bmc.2017.12.030
   PubMed Web of Science ®Google Scholar
• Kim HS, Ortiz D, Kadayat TM, et al. Optimization of orally bioavailable Antileishmanial 2,4,5-Trisubstituted Benzamides. J Med Chem. 2023;66(11):7374–7386. doi: 10.1021/acs.jmedchem.3c00056
   PubMed Web of Science ®Google Scholar
• Miyajima Y, Noguchi-Yachide T, Ochiai K, et al. Physicochemical characterization of B-hydroxyphenyl phosphine borane derivatives and their evaluation as nuclear estrogen receptor ligands. RSC Med Chem. 2024;15(1):119–126. doi: 10.1039/d3md00350g
   PubMedGoogle Scholar
• Li Z, Hao Y, Yang C, et al. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity. Eur J Med Chem. 2022;228:114036. doi: 10.1016/j.ejmech.2021.114036
   PubMed Web of Science ®Google Scholar
• Bachovchin KA, Sharma A, Bag S, et al. Improvement of aqueous solubility of lapatinib-derived analogues: identification of a Quinolinimine lead for human African Trypanosomiasis drug development. J Med Chem. 2019;62(2):665–687. doi: 10.1021/acs.jmedchem.8b01365
   PubMed Web of Science ®Google Scholar
• Dhameliya TM, Patel KI, Tiwari R, et al. Design, synthesis, and biological evaluation of benzo[d]imidazole-2-carboxamides as new anti-TB agents. Bioorg Chem. 2021;107:104538. doi: 10.1016/j.bioorg.2020.104538
   PubMed Web of Science ®Google Scholar
• Wang C, Pei Y, Wang L, et al. Discovery of (1H-Pyrazolo[3,4-c]pyridin-5-yl)sulfonamide Analogues as Hepatitis B Virus Capsid assembly modulators by conformation constraint. J Med Chem. 2020;63(11):6066–6089. doi: 10.1021/acs.jmedchem.0c00292
   PubMed Web of Science ®Google Scholar
• Rahman MS, Esfahani SH, Nozohouri S, et al. Structure-activity relationship studies of functionalized aromatic peptidomimetics as neurolysin activators. Bioorg Med Chem Lett. 2022;64:128669. doi: 10.1016/j.bmcl.2022.128669
   PubMed Web of Science ®Google Scholar
• Josa-Cullere L, Galan SRG, Cogswell TJ, et al. Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines. Eur J Med Chem. 2023;258:115509. doi: 10.1016/j.ejmech.2023.115509
   PubMed Web of Science ®Google Scholar
• Beveridge J, Tran E, Deora GS, et al. Novel Diarylthioether compounds as agents for the treatment of Chagas disease. J Med Chem. 2023;66(2):1522–1542. doi: 10.1021/acs.jmedchem.2c01725
   PubMed Web of Science ®Google Scholar
• Shahbazi Nia S, Hossain MA, Ji G, et al. Studies on diketopiperazine and dipeptide analogs as opioid receptor ligands. Eur J Med Chem. 2023;254:115309. doi: 10.1016/j.ejmech.2023.115309
   PubMed Web of Science ®Google Scholar
• Boudreau MW, Mulligan MP, Shapiro DJ, et al. Activators of the anticipatory unfolded protein response with enhanced selectivity for estrogen receptor positive breast cancer. J Med Chem. 2022;65(5):3894–3912. doi: 10.1021/acs.jmedchem.1c01730
   PubMed Web of Science ®Google Scholar
• Laghezza A, Luisi G, Caradonna A, et al. Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors. Bioorg Med Chem. 2020;28(3):115257. doi: 10.1016/j.bmc.2019.115257
   PubMed Web of Science ®Google Scholar
• Fernandes GFS, Campos DL, Da Silva IC, et al. Benzofuroxan derivatives as potent agents against multidrug-resistant mycobacterium tuberculosis. ChemMedchem. 2021;16(8):1268–1282. doi: 10.1002/cmdc.202000899
   PubMed Web of Science ®Google Scholar
• Mahy W, Patel M, Steadman D, et al. Screening of a custom-designed acid fragment library identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as inhibitors of Notum Carboxylesterase activity. J Med Chem. 2020;63(17):9464–9483. doi: 10.1021/acs.jmedchem.0c00660
   PubMed Web of Science ®Google Scholar
• Morozova A, Chan SC, Bayle S, et al. Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties. Eur J Med Chem. 2024;266:116101. doi: 10.1016/j.ejmech.2023.116101
   PubMed Web of Science ®Google Scholar
• Sharma LK, Yun MK, Subramanian C, et al. LipE guided discovery of isopropylphenyl pyridazines as pantothenate kinase modulators. Bioorg Med Chem. 2021;52:116504. doi: 10.1016/j.bmc.2021.116504
   PubMed Web of Science ®Google Scholar
• Kozlova A, Thabault L, Liberelle M, et al. Rational design of original fused-cycle selective inhibitors of Tryptophan 2,3-Dioxygenase. J Med Chem. 2021;64(15):10967–10980. doi: 10.1021/acs.jmedchem.1c00323
   PubMed Web of Science ®Google Scholar
• Dennis AS, V D W H, Walker DK. Pharmacokinetics and metabolism in drug design. 2006.
   Google Scholar
• Wilson P, Stewart A, Flournoy V, et al. Liquid chromatographic determination of nystatin in pharmaceutical preparations. J AOAC Int. 2001;84(4):1050–1055. doi: 10.1093/jaoac/84.4.1050
   PubMed Web of Science ®Google Scholar
• Duan YJ, Fu L, Zhang XC, et al. Improved GNNs for Log D(7.4) prediction by transferring knowledge from low-fidelity data. J Chem Inf Model. 2023;63(8):2345–2359. doi: 10.1021/acs.jcim.2c01564
   PubMed Web of Science ®Google Scholar
• Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem. 2008;51(4):817–834. doi: 10.1021/jm701122q
   PubMed Web of Science ®Google Scholar
• Leung CS, Leung SS, Tirado-Rives J, et al. Methyl effects on protein-ligand binding. J Med Chem. 2012;55(9):4489–4500. doi: 10.1021/jm3003697
   PubMed Web of Science ®Google Scholar
• Kim SG, Novak RF. The induction of cytochrome P4502E1 by nitrogen- and sulfur-containing heterocycles: expression and molecular regulation. Toxicol Appl Pharmacol. 1993;120(2):257–265. doi: 10.1006/taap.1993.1110
   PubMed Web of Science ®Google Scholar
• Atz K, Cotos L, Isert C, et al. Prospective de novo drug design with deep interactome learning. Nat Commun. 2024;15(1):3408. doi: 10.1038/s41467-024-47613-w
   PubMedGoogle Scholar